Nkarta misses Q4 estimates as cash runway extends to 2029
Biotech posts wider quarterly loss but advances autoimmune trials amid oversold conditions
Nkarta Inc. shares slipped in late March trading after the clinical-stage biotechnology company reported a wider-than-expected quarterly loss, though investors found encouragement in the company's extended cash runway and progress with its experimental cell therapy platform.
The South San Francisco-based company reported a fourth-quarter net loss of $27.4 million, or 37 cents per share, missing analyst projections that had ranged from 32 to 34 cents per share. The quarterly performance compared with a $25.9 million loss in the year-ago period. For the full year 2025, Nkarta recorded a net loss of $104.1 million, or $1.41 per share, representing an improvement from the $108.8 million loss in 2024.
Despite the earnings shortfall, the stock's technical metrics suggest the shares may be oversold. The 14-day Relative Strength Index recently stood at approximately 31, a level that typically indicates a security has fallen too far too fast and could be due for a rebound. The stock declined nearly 6% following the earnings announcement, though this movement remained within the company's historical volatility patterns surrounding quarterly reports.
The most significant development from the quarter emerged from Nkarta's clinical pipeline. The company reported that dose escalation for NKX019 has advanced to 4 billion cells per dose on days 0, 3 and 7, totaling 12 billion cells per cycle. NKX019 is a chimeric antigen receptor natural killer (CAR-NK) cell therapy designed to treat various autoimmune diseases by targeting CD19-expressing B cells.
Nkarta is actively enrolling patients in two key trials: Ntrust-1, evaluating NKX019 for active lupus nephritis and primary membranous nephropathy, and Ntrust-2, studying the therapy for systemic sclerosis, idiopathic inflammatory myopathy and ANCA-associated vasculitis. Both are Phase 1/2 multi-center, open-label, dose-escalation studies. Enrollment remains open in investigator-sponsored trials for generalized myasthenia gravis and systemic lupus erythematosus.
Paul J. Hastings, Nkarta's chief executive officer, characterized 2025 as a strategically important year marked by the onboarding of a clinical team with extensive autoimmune experience and workforce adjustments to responsibly manage investor capital. "We look forward to sharing a comprehensive clinical update from Ntrust-1 and Ntrust-2 later this year at a medical conference," Hastings stated in the earnings release.
Perhaps most reassuring for investors is the company's financial position. As of December 31, 2025, Nkarta held cash, cash equivalents, restricted cash and investments totaling $295.1 million, which management believes will fund operations into 2029. This substantial runway provides the company with flexibility to advance its clinical programs without the immediate need to raise additional capital through dilutive stock offerings.
The company's full-year research and development expenses reached $90.4 million, while general and administrative costs totaled $31.6 million, reflecting the investment required to advance multiple clinical programs simultaneously.
Analyst sentiment on Nkarta remains broadly positive despite the earnings miss. The consensus rating stands at "Moderate Buy" with an average price target of approximately $13.25, according to MarketBeat data. This suggests potential upside of more than 500% from current levels around $2.13 per share. Individual analyst price targets range from $8 to $25, indicating significant divergence in expectations for the company's prospects.
Nkarta's market capitalization currently stands at approximately $152 million, with institutional investors holding about 78% of outstanding shares. The stock trades at 0.46 times book value, suggesting investors have substantially discounted the company's assets amid broader challenges facing the biotechnology sector.
The company now faces a critical 2026 period that could determine its trajectory. Initial clinical data from the Ntrust-1 and Ntrust-2 trials, expected to be presented at a medical conference in the first half of 2026, will represent the first meaningful readouts for NKX019 in autoimmune indications. Success in these early-stage studies could validate the CAR-NK platform's potential beyond oncology applications and potentially support a re-rating of the shares.
However, the company is not without risks. Clinical-stage biotechnology companies operate with high uncertainty, and any safety concerns or lack of efficacy in the upcoming data readouts could pressure the stock further. Additionally, the broader market environment for pre-profit biotechnology companies remains challenging, with investors showing increased selectivity in allocating capital to the sector.
Nkarta's decision to pivot part of its platform toward autoimmune diseases represents a strategic bet on a large and underserved market. If successful, CAR-NK therapies could offer advantages over existing treatments, including potentially lower manufacturing costs and improved safety profiles compared with CAR-T cell therapies.
As the company advances into 2026, investors will focus on three key milestones: the safety and efficacy signals from the initial Ntrust data, the pace of patient enrollment across all ongoing trials, and management's ability to execute on its clinical plans while maintaining financial discipline. With a cash runway extending nearly three years, Nkarta has time to demonstrate whether its proprietary cell therapy platform can deliver meaningful clinical benefits for patients with autoimmune diseases.